Continuous Measurement of Glymphatic Activity in the Human Brain During Sleep-Wake States

Healthy Clinical Trial

Official title:

Continuous Measurement of Glymphatic Activity in the Human Brain During Sleep-Wake States

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06060054
• Other study ID #: AC.2022.03
• Status: Completed
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: May 10, 2023

Study information

• Verified date: December 2023
• Source: Applied Cognition
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a cross-over randomized study to validate the Sponsor investigational medical device against measurements of glymphatic function from MRI-based neuroimaging, EEG, blood biomarkers and cognitive tests in healthy older volunteers.

Description:

The study population will consist of healthy individuals, ages 50 to 65, that are cognitively normal and do not have a medical history of neurological or sleep disorder, cardiovascular disease, hypertension, or diabetes. The objectives of this study are to define whether sleep- and wake-associated device measurements (i) faithfully reflect glymphatic function measured by non-invasive MRI measures of glymphatic function; (ii) replicate pre-clinical findings between sleep EEG power bands and glymphatic flow; (iii) predict plasma levels of Alzheimer's disease (AD)-related biomarkers; and (iv) predict morning cognitive performance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: May 10, 2023
• Est. primary completion date: May 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 50 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Participants must have a Montreal Cognitive Assessment (MoCA) score at least 26.

2. Participants must have a Geriatric Depression Scale (GDS) 15-item score of 4 or less.

Exclusion Criteria:

1. Participants with a formal diagnosis of any sleep disorder (e.g., sleep apnea on positive-airway-pressure (PAP) therapy, insomnia, restless leg syndrome, circadian rhythm sleep disorder, parasomnia).

2. Participants with a history of significant neurological disease or history of epilepsy.

3. Participants with cardiovascular disease or cardiovascular risk factors (smoking or hypertension).

4. Participants with diabetes.

5. Participants with traumatic brain injury, or serious mental illness including bipolar disorder, schizophrenia, major depressive disorder or post-traumatic stress disorder.

6. Participants who have taken in the past 30 days prescribed or over-the-counter (OTC) stimulants, sleeping medications, or psychiatric medications including antidepressants.

7. Participants who consume more than 400 mg/day of caffeine. Participants will be required to not consume caffeine beginning 12pm on the day-of the sleep study.

8. Female Participants who consume more than 3 alcoholic drinks on any day or more than 7 drinks per week. Male participants who consume more than 4 alcoholic drinks on any day or more than 14 drinks per week.

9. Participants who have or will have travelled across time zones 10 days prior to either Study Visit or whose first and second Study Visits span Daylight Savings time change (November 6, 2022).

10. Participants with travel plans or conflicts that would prevent them from either Study Visit.

11. Participants who are enrolled in other research studies and are receiving an investigational drug within 30 days of the planned start date.

12. Participants who have any condition that, in the opinion of the Sponsor Principal Investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements.

13. Participants with absolute or relative contraindications to MRI imaging based on current up-to-date screening questionnaires including claustrophobia, inability to lie still on their back for 30-45 minutes or require sedation prior to the MRI.

14. Participants with a head circumference greater than 60 cm that would prevent use of a high-resolution 64 channel MRI head coil required for this study

15. Participants who have a pre-planned surgery or medical procedure that would interfere with the conduct of the study.

16. Participants who have an implanted medical device or contraindications that would exclude MRIs

17. Participants with a serious infection requiring medical attention in the past 30 days

Related Conditions & MeSH terms

• Healthy

Intervention

Diagnostic Test:
• Device measurements
Overnight device measurements

Locations

Country	Name	City	State
United States	University of Washington Department of Radiology (DISC)	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
Applied Cognition	Oregon Health and Science University, University of Washington

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MRI	Define whether sleep- and wake-associated device measurements (impedances in milli-ohms) faithfully reflect glymphatic function measured by non-invasive MRI measures of glymphatic function: (i) diffusion-based intravoxel incoherent motion (IVIM)-MRI (long-distance water transport) (diffusion signal, a.u.), (ii) fast functional MRI (f-MRI) low-frequency vasomotor oscillations, Hz, (iii) T1/FLAIR-based assessment of MRI-visible perivascular spaces (MV-PVS) that are structural indicators of perivascular impairment, (a.u.); (iv) multi-echo arterial spin-labeling (ME-ASL)-MRI (glial-vascular water transport) (flow in ml/sec); (v) and phase-contrast (PC)-MRI (aqueductal cerebral spinal fluid (CSF) flow) (flow in ml/sec).	Immediately before and immediately after the intervention
Secondary	Sleep EEG	Correlations between device overnight measurements (impedances in milli-ohms) and overnight recorded EEG power bands (relative delta, theta, alpha and beta power in %) replicate pre-clinical correlations of glymphatic flow (measured using 2-photon microscopy in a.u.) and EEG power bands (relative delta, theta, alpha and beta power in %).	During the intervention
Secondary	Blood biomarkers	Device overnight measurements predict overnight changes in amyloid beta40, beta42, n-tau 181, n-tau 217, p-tau 181, p-tau 217 blood biomarkers.	Immediately before and immediately after the intervention
Secondary	Cognitive function	Device overnight measurements predict morning cognitive performance based on aggregated standardized scores (mean of 0 and standard deviation of 1) of Trail Making Tests A&B (time in seconds), symbol digit modality test (SDMT) (number correct), psychomotor vigilance test (PVT) (mean and standard deviation of reaction time) and digits forward recall (maximum number of correctly recalled digits).	Immediately after the intervention